2024 RNA Discovery Retreat July 2, 2024 By ckalnen Filed Under: More from UNC Lineberger Comprehensive Cancer Center ASBMB Today: Behind the bench: How research leaders create the conditions for discovery News Medical: Phase III trial tests MRD-guided treatment for patients with ER-positive/HER2-negative breast cancer FirstWord Pharma: Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
